Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRX NASDAQ:KYMR NASDAQ:PRAX NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$8.76-0.1%$7.63$1.95▼$12.43$9.19B0.0312.48 million shs9.29 million shsKYMRKymera Therapeutics$114.67+4.9%$85.81$36.65▼$130.05$8.99B2.021.25 million shs1.13 million shsPRAXPraxis Precision Medicines$334.79-4.5%$314.47$37.19▼$366.52$9.77B2.71701,758 shs740,097 shsSLSSELLAS Life Sciences Group$14.76-4.5%$7.54$1.39▼$15.88$3.04B2.59.08 million shs21.50 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio+0.69%+21.47%+16.62%+14.34%+224.81%KYMRKymera Therapeutics+1.11%+9.92%+34.27%+31.25%+147.78%PRAXPraxis Precision Medicines+6.95%+15.55%+0.17%+8.81%+715.26%SLSSELLAS Life Sciences Group+24.70%+81.13%+65.95%+265.25%+692.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$8.76-0.1%$7.63$1.95▼$12.43$9.19B0.0312.48 million shs9.29 million shsKYMRKymera Therapeutics$114.67+4.9%$85.81$36.65▼$130.05$8.99B2.021.25 million shs1.13 million shsPRAXPraxis Precision Medicines$334.79-4.5%$314.47$37.19▼$366.52$9.77B2.71701,758 shs740,097 shsSLSSELLAS Life Sciences Group$14.76-4.5%$7.54$1.39▼$15.88$3.04B2.59.08 million shs21.50 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio+0.69%+21.47%+16.62%+14.34%+224.81%KYMRKymera Therapeutics+1.11%+9.92%+34.27%+31.25%+147.78%PRAXPraxis Precision Medicines+6.95%+15.55%+0.17%+8.81%+715.26%SLSSELLAS Life Sciences Group+24.70%+81.13%+65.95%+265.25%+692.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 2.71Moderate Buy$14.2062.10% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$121.415.88% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$569.6370.15% UpsideSLSSELLAS Life Sciences Group 2.00Hold$10.00-32.25% DownsideCurrent Analyst Ratings BreakdownLatest SLS, PRAX, IBRX, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026KYMRKymera Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $125.006/29/2026KYMRKymera Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$117.00 ➝ $155.006/29/2026KYMRKymera Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$116.00 ➝ $136.006/29/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$537.00 ➝ $575.006/26/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$106.00 ➝ $129.006/25/2026KYMRKymera Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$134.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$449.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy6/8/2026KYMRKymera Therapeutics Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$97.006/8/2026KYMRKymera Therapeutics Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026PRAXPraxis Precision Medicines TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$113.29M80.98N/AN/A($0.51) per share-17.18KYMRKymera Therapeutics$39.21M240.57N/AN/A$19.42 per share5.90PRAXPraxis Precision Medicines$8.55M1,091.69N/AN/A$34.85 per share9.61SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest SLS, PRAX, IBRX, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A6.676.66KYMRKymera TherapeuticsN/A10.8110.81PRAXPraxis Precision MedicinesN/A15.8815.88SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%KYMRKymera TherapeuticsN/APRAXPraxis Precision Medicines67.84%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio66.10%KYMRKymera Therapeutics15.98%PRAXPraxis Precision Medicines3.00%SLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio5901.05 billion355.05 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableSLS, PRAX, IBRX, and KYMR HeadlinesRecent News About These CompaniesDoes SELLAS (SLS) Executive Severance Reset Hint at M&A Readiness or Standalone Ambition?18 minutes ago | uk.finance.yahoo.comWhy Sellas Remains A Strong Sell After Doubling In Price18 minutes ago | seekingalpha.comSELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?June 30 at 10:04 AM | benzinga.comSellas Life (SLS) Climbs to Record High on Acquisition BuzzJune 30 at 3:53 AM | finance.yahoo.comSellas Life Sciences shares break out to new 52-week high: What's driving the momentum?June 29 at 5:52 PM | msn.comIs SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?June 29 at 4:10 PM | insidermonkey.comWhy did SLS, MRNA, ABCL stocks surge to 52-week highs last week?June 28 at 12:57 AM | msn.comSellas Life Sciences: The AML Platform Is More Interesting Than The Binary EventJune 27 at 5:02 AM | seekingalpha.comSELLAS Life Sciences jumps as traders focus on imminent REGAL trial catalyst and stronger cash positionJune 26, 2026 | quiverquant.comQSELLAS stock hits new highs: What's happening today?June 26, 2026 | msn.comWhat's driving SLS stock higher today and what comes next?June 26, 2026 | invezz.comISLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout ChatterJune 26, 2026 | finance.yahoo.comSellas (SLS) Extends Rally, New Filing Hints at Company TakeoverJune 26, 2026 | insidermonkey.comSLS stock up 13% as executive severance updates reignite buyout speculationJune 25, 2026 | msn.comSLS stock slips overnight: Shareholders approve 20M new shares, CEO awarded 1M RSUsJune 22, 2026 | msn.comWhat Does Strong Shareholder Support Mean for SELLAS Life Sciences Group (NASDAQ:SLS)?June 19, 2026 | kalkinemedia.comKSELLAS Stockholders Approve Governance and Equity Plan ChangesJune 18, 2026 | tipranks.comAll eyes on SLS stock ahead of annual shareholder meet – what's on the agenda?June 16, 2026 | msn.comSLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment DisputeJune 5, 2026 | finance.yahoo.comSELLAS Life Sciences boosts liquidity through warrant exercisesJune 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLS, PRAX, IBRX, and KYMR Company DescriptionsImmunityBio NASDAQ:IBRX$8.76 -0.01 (-0.11%) Closing price 04:00 PM EasternExtended Trading$8.76 0.00 (-0.06%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Kymera Therapeutics NASDAQ:KYMR$114.67 +5.35 (+4.89%) Closing price 04:00 PM EasternExtended Trading$117.86 +3.19 (+2.78%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Praxis Precision Medicines NASDAQ:PRAX$334.79 -15.77 (-4.50%) Closing price 04:00 PM EasternExtended Trading$339.00 +4.21 (+1.26%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.SELLAS Life Sciences Group NASDAQ:SLS$14.76 -0.69 (-4.47%) Closing price 04:00 PM EasternExtended Trading$14.42 -0.34 (-2.32%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
